Non Hodgkin's Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-10-09
Oct 9, 2021
N
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
  • +1 more
2021-10-09
Oct 9, 2021
G
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL - 2017
Terminated
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • hLL1-DOX (IMMU-115)
  • Newark, Delaware
  • +5 more
2021-10-06
Oct 6, 2021
S
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma - 2015
Terminated
Has Results
  • Non-Hodgkin's Lymphoma
  • Berkeley, California
  • +8 more
2021-09-06
Sep 6, 2021
H
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Tucson, Arizona
  • +22 more
2021-09-30
Sep 30, 2021
H
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Recruiting
  • Non-Hodgkin's Lymphoma
  • Los Angeles, California
  • +40 more
2021-09-27
Sep 27, 2021
U
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
Active, not recruiting
  • Hodgkin's Lymphoma
  • +8 more
  • Reduced intensity haplodentical stem cell transplant
  • Myeloablative haploidentical stem cell transplant
  • Birmingham, United Kingdom
  • +11 more
2021-09-27
Sep 27, 2021
A
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma - 2021
Completed
  • Non-Hodgkin's Lymphoma
  • Duarte, California
  • +16 more
2021-09-23
Sep 23, 2021
A
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Phoenix, Arizona
  • +30 more
2021-09-23
Sep 23, 2021
S
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Plasma Cell Myeloma
  • Hematopoietic Cell Transplantation
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2021-09-21
Sep 21, 2021
M
MB-CART20.1 Lymphoma
Active, not recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • +3 more
  • MB-CART20.1
  • Cologne, Germany
  • +1 more
2021-09-20
Sep 20, 2021
H
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT - 2021
Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • +7 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-09-14
Sep 14, 2021
U
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
Active, not recruiting
  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Miami, Florida
    University of Miami
2021-09-09
Sep 9, 2021
N
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-09-04
Sep 4, 2021
G
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer - 2021
Completed
  • Solid Cancers
  • Non-Hodgkin's Lymphoma
  • Scottsdale, Arizona
  • +30 more
2021-09-03
Sep 3, 2021
N
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Recruiting
  • Leukemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-09-02
    Sep 2, 2021
    N
    Reduced Intensity Conditioning Transplant Using Haploidentical Donors - 2020
    Completed
    • Chronic Myelogenous Leukemia
    • +9 more
    • Atlanta, Georgia
      Northside Hospital
    2021-08-30
    Aug 30, 2021
    T
    Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies - 2018
    Completed
    • Non-Hodgkin's Lymphoma
    • +3 more
    • Sarasota, Florida
    • +6 more
    2021-08-20
    Aug 20, 2021
    G
    Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL - 2017
    Terminated
    • Non-hodgkin's Lymphoma
    • +5 more
    • Newark, Delaware
    • +4 more
    2021-08-12
    Aug 12, 2021
    G
    Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
    Completed
    • Non-Hodgkin's Lymphoma
    • Lymphoma, B-Cell
    • radiolabeled epratuzumab
    • (no location specified)
    2021-08-12
    Aug 12, 2021
    G
    Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma - 2007
    Completed
    • Non-Hodgkin's Lymphoma
    • +2 more
    • Lille, Cedex, France
    • +2 more
    2021-08-12
    Aug 12, 2021
    G
    Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma - 2007
    Completed
    • Non-Hodgkin's Lymphoma
    • hA20-humanized anti-CD20 antibody
    • New York, New York
    • +2 more
    2021-08-12
    Aug 12, 2021
    B
    CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
    Active, not recruiting
    • Acute Lymphoblastic Leukemia
    • +3 more
    • Allodepleted T Cells
    • Houston, Texas
    • +1 more
    2021-08-13
    Aug 13, 2021
    C
    Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
    Recruiting
    • Non-hodgkin's Lymphoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    2021-08-09
    Aug 9, 2021
    E
    A Study of LY3023414 in Participants With Advanced Cancer
    Active, not recruiting
    • Advanced Cancer
    • +5 more
    • Los Angeles, California
    • +7 more
    2021-08-05
    Aug 5, 2021